These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29111151)

  • 1. Experimental optimization of Lornoxicam liposomes for sustained topical delivery.
    Joseph J; B N VH; D RD
    Eur J Pharm Sci; 2018 Jan; 112():38-51. PubMed ID: 29111151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation.
    El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB
    Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.
    Kumbhar D; Wavikar P; Vavia P
    AAPS PharmSciTech; 2013 Sep; 14(3):1072-82. PubMed ID: 23818079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and evaluation of proniosomes containing lornoxicam.
    Madan JR; Ghuge NP; Dua K
    Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilosomes as Promising Nanovesicular Carriers for Improved Transdermal Delivery: Construction, in vitro Optimization, ex vivo Permeation and in vivo Evaluation.
    Ahmed S; Kassem MA; Sayed S
    Int J Nanomedicine; 2020; 15():9783-9798. PubMed ID: 33324052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
    Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
    Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers.
    Li K; Gao S; Tian B; Shi Y; Lv Q; Han J
    Curr Drug Deliv; 2018; 15(3):424-435. PubMed ID: 29219057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro & in vivo studies on lornoxicam loaded nanoemulsion gels for topical application.
    Dasgupta S; Ghosh SK; Ray S; Kaurav SS; Mazumder B
    Curr Drug Deliv; 2014; 11(1):132-8. PubMed ID: 24266509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
    El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA
    Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
    Hamza Yel-S; Aburahma MH
    Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam.
    Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T
    Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal Lipid Nanocarriers: A Potential Delivery System for Lornoxicam.
    Dasgupta S; Ray S; Dey S; Pal P; Mazumder B
    Pharm Nanotechnol; 2017; 5(1):32-43. PubMed ID: 28948909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.
    Abdelbary GA; Aburahma MH
    J Liposome Res; 2015; 25(2):107-21. PubMed ID: 25058447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
    Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
    Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
    Al-Mahallawi AM; Abdelbary AA; Aburahma MH
    Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis.
    Pawar VA; Manjappa AS; Murumkar PR; Gajaria TK; Devkar RV; Mishra AK; Yadav MR
    Eur J Pharm Sci; 2018 Dec; 125():11-22. PubMed ID: 30219410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.
    Shahzad Y; Khan Q; Hussain T; Shah SN
    Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proniosomes as a carrier system for transdermal delivery of tenoxicam.
    Ammar HO; Ghorab M; El-Nahhas SA; Higazy IM
    Int J Pharm; 2011 Feb; 405(1-2):142-52. PubMed ID: 21129461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tri/tetra-block co-polymeric nanocarriers as a potential ocular delivery system of lornoxicam: in-vitro characterization, and in-vivo estimation of corneal permeation.
    Salama AH; Shamma RN
    Int J Pharm; 2015 Aug; 492(1-2):28-39. PubMed ID: 26151106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desosomes and desimicelles - a novel vesicular and micellar system for enhanced oral delivery of poorly soluble drug: Optimization of in vitro characteristics and in vivo performance.
    Said AR; Asaad GF; Shabana ME; Sayed AS; Elfeky DH; Mohamed Ali H; Adel Abdelfattah A; M El-Husseiny H; El-Dakroury WA
    Eur J Pharm Biopharm; 2024 Jul; 200():114324. PubMed ID: 38759898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.